FDA approves Pfizer’s HYMPAVZI for breakthrough hemophilia treatment

In a major leap for hemophilia patients, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval for HYMPAVZI ... Read More